Business
Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR
Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Dru...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Management mitigating risk by adding clinical sites in two countries and making protocol changes\n \n \n Timing for top-line results remains unchanged, still expected in Q4 2022\n \n \n \n \n VICTORIA, BC\n \n ,\n \n Dec. 2, 2021\n \n /CNW/ -\n \n December 2\n \n , 2021 - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today provided an update on its ongoing Phase 2 trial that is evaluating the safety and efficacy of its drug candidate EP-104IAR as a treatment for knee osteoarthritis.\n \n \n The Company is expanding its clinical trial locations to two additional countries to facilitate more rapid and consistent patient screening in a constantly evolving pandemic environment. Eupraxia anticipates that costs associated with expanding the number of trial sites will be immaterial. In addition, several updates have been initiated in the trial's protocol to facilitate more rapid patient screening.\n \n \n \"As the COVID-19 pandemic continues to place pressure on clinical trial execution around the world, and the situation evolves across\n \n Europe\n \n , including\n \n Denmark\n \n , we believe it is prudent to proactively take steps to further mitigate risk in our trial in response to these challenges,\" said Dr.\n \n James Helliwell\n \n , Chief Executive Officer of Eupraxia. \"While we are actively dosing patients, management believes these changes will help build on the patient enrolment progress made to date and continue to support our target for top-line data readout at the end of 2022. In addition, we are maintaining our focus on the high quality of the trial and remain uncompromising on the rigour of our protocol.\"\n \n \n More information on the Company's Phase 2 trial, including new site locations will be available here:\n \n \...